An observational study in Retinal Detachment, Full Thickness Macular Hole and Epiretinal Membrane, sponsored by Allen C. Ho, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-17.
Sponsored by Allen C. Ho, MD · Observational
Prospective study evaluating the role of inflammasomes in cell death in retinal detachment, full thickness macular hole, and epiretinal membrane. The investigators are collecting vitreous and subretinal fluid samples from patients with these conditions and evaluating activity of the inflammasome pathway with established assays.
Photoreceptor cell death is the main cause of vision loss in many retinal disorders, including retinal detachment (RD). While apoptosis is the most studied form of cell death, the investigators believe patients with RDs may have photoreceptor cell death from a distinct pathway of programmed cell death called pyroptosis which also involves an inflammatory response. Pyroptosis is distinct from apoptosis in that it requires the activation of a protein oligomer complex called an inflammasome. The inflammasome is a pro-inflammatory complex composed of apoptosis-associated speck-like protein containing a CARD (ASC), nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor (NLR) family or pyrin and HIN domain (PYHIN) family, and caspase-11. Activation of the inflammasome complex leads to activation of capspase 1 proteolytic activity to cleave and synthesize IL-1β and IL-18. As such the investigators believe inflammasomes and its activated products may play a strong role in the inflammatory and cell death pathway for photoreceptor cells in human retina. Studies using animal models of RD have already confirmed the presence of IL-1β activation2, however, the presence of IL-18 needs to be confirmed in human detached retinas. In a study performed on the detached retinas in mice, researchers were able to show activation of inflammasomes leading to photoreceptor cell death. While researchers are unable to determine the cellular source of the inflammasomes they were able to show that activation inflammasomes closely follows animal models. Currently there is no method to rescue photoreceptors cells from the mediated cell death pathway despite surgical intervention. Thus, current visual prognosis and prevention of further photoreceptor loss due to a RD is likely dependent on the time of surgical intervention before further detachment and further cell death can occur. As such, the purpose of this current study is to confirm the presence of inflammasome activation as well as the synthesis of its products, IL-1β and IL-18, in patients with rhegmatogenous retinal detachments. Both inflammasomes and its products IL-1β and IL-18 may be involved in cell pyroptosis, a programmed cell death distinct from apoptosis. Due to a lack of treatment for the rescue of photoreceptor cells from cell death after a retinal detachment, this study can provide novel strategies to inhibit cell death.
199 studies on the registry are indexed under Retinal Detachment; 29 are open to participants now.
This study's enrollment of 41 is below the median of 60 across 58 observational studies indexed under Retinal Detachment.
Browse Retinal Detachment studies →This is the only study on the registry with Allen C. Ho, MD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adults with retinal detachment, macular hole, or epiretinal membrane.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vitreous fluid from retinal detachment treated with pars plana vitrectomy
Procedure: Pars plana vitrectomy
Subretinal fluid from retinal detachment treated with external drainage.
Procedure: External drainage
Vitreous fluid from patients treated for macular hole
Procedure: Pars plana vitrectomy
Vitreous fluid from patients treated for epiretinal membrane
Procedure: Pars plana vitrectomy
Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
Standard of care treatment for retinal detachment.
Presence of inflammasomes and their active products
Presence of inflammasomes and their active products in patients with retinal detachment treated with vitrectomy or external drainage, macular holes treated with vitrectomy, and epiretinal membranes treated with vitrectomy
Time frame: Day of surgery
Difference in inflammasome levels among samples
Difference in inflammasome pathway activation between retinal detachment, macular hole, and epiretinal membrane samples
Time frame: Day of surgery
Plan to share: Undecided — manuscript under development
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.